The First Affiliated Hospital of Soochow University: Leukemia trials

The registry lists 47 Leukemia studies with The First Affiliated Hospital of Soochow University as lead sponsor. 22 are open to participants now and 0 have results posted.

Early Phase 1 2Phase 1 7Phase 2 27Phase 3 15Phase 4 1No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid LeukemiaRecruitingNCT07028073Phase 1/2
• a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid LeukemiaRecruitingNCT07007949Phase 2
• A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AMLRecruitingNCT06879847Not applicable
• Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic LeukemiaRecruitingNCT06696833Early Phase 1
• BuCy Vs. TBICy for Allo-HSCT in T-ALL PatientsNot yet recruitingNCT06673459Phase 3
• Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALLRecruitingNCT06578546Phase 2
• Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute LeukemiaNot yet recruitingNCT06559644Early Phase 1
• Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia PatientsEnrolling by invitationNCT06544109Phase 2/3
• Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML PatientsRecruitingNCT06394011Phase 2
• Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALLRecruitingNCT06393985Phase 2
• Haplo-cord HCT vs. Haplo-HCT for T-ALL PatientsRecruitingNCT06381817Phase 3
• CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).RecruitingNCT06078306Phase 2
• Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCTRecruitingNCT05823714Phase 2
• CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05822037Not applicable
• Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCTRecruitingNCT05809167Phase 2
• Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AMLRecruitingNCT05805098Phase 2/3
• Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) PatientsNot yet recruitingNCT05805072Not applicable
• ThisCART19A Bridging to alloHSCT for R/R B-ALLRecruitingNCT05679687Phase 1
• Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALLRecruitingNCT05559450Phase 2
• Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid LeukemiaRecruitingNCT05504408
• Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05023707Phase 1/2
• Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）RecruitingNCT04534634Phase 2
• Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) PatientsStatus unknownNCT05951855Phase 2
• M-PTCy vs BuCy in Haploidentical HSCT for Acute LeukemiaStatus unknownNCT05739630Phase 2/3
• Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALLStatus unknownNCT05578378Phase 2/3
• Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP PatientsCompletedNCT05433532Phase 2
• CAV Regimen Bridging to HSCT for R/R ALCompletedNCT05190549Phase 2
• Venetoclax Based Regimen for R/R T-ALLCompletedNCT05149378Phase 2
• Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction TherapiesStatus unknownNCT05123352
• Application of Nanopore Sequencing in Newly Diagnosed Acute Myeloid Leukemia Patients With Bloodstream InfectionStatus unknownNCT05016752
• Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)Status unknownNCT04884984Phase 1/2
• Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With ALStatus unknownNCT04846439Phase 1/2
• Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute LeukemiaStatus unknownNCT04762485Phase 1/2
• Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk FeaturesStatus unknownNCT04752527Phase 2
• PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AMLStatus unknownNCT04722952Phase 3
• Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers PatientsStatus unknownNCT04446130Phase 3
• CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid LeukemiaStatus unknownNCT04351022Phase 1/2
• Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML PatientsStatus unknownNCT04087967Phase 3
• Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60Status unknownNCT04083911Phase 3
• CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03985007Phase 2
• Haplo HCT vs Haplo-cord HCT for Patients With AMLCompletedNCT03719534Phase 3
• Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCTStatus unknownNCT03715621
• Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCTStatus unknownNCT03256071Phase 2/3
• Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT02323022Phase 3
• Haplo-SCT vs ASCT With or Without Decitabine in AML CR1Status unknownNCT02059720Phase 3
• Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeStatus unknownNCT01809392Phase 2/3
• Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell TransplantationStatus unknownNCT01806116Phase 4